Compare Southwest Airlines Co (LUV) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Southwest Airlines Co vs Sana Biotechnology Inc — how do they compare? Southwest Airlines Co trades at $44.88 (market cap $22.27B), while Sana Biotechnology Inc trades at $3.83 (market cap $1.13B). The key difference: Southwest Airlines Co is far larger — about 19.7× Sana Biotechnology Inc's market cap, and Southwest Airlines Co pays a 1.58% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| LUV | SANA | |
|---|---|---|
Market Cap | $22.27B | $1.13B |
Sector | Industrials | Health |
52-Week High | $54.80 | $5.92 |
52-Week Low | $29.67 | $2.68 |
Enterprise Value | $25.37B | $1.05B |
Dividend Yield | 1.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Southwest Airlines (LUV) trades at $44.91, showing minimal daily movement. The stock exhibits a bearish technical trend, with key support at $45 and resistance at $46. Fundamentally, revenue grew to $28.06B in 2025, though net income margin compressed to 1.57%. Recent Q2 2026 earnings beat expectations with EPS of $0.94 versus $0.51 expected, while Q1 2026 missed. The company maintains a dividend of $0.18 per share and is focusing on business travel expansion.
LUV presents a mixed outlook. Analyst consensus is a Buy with a $53.86 price target, implying ~20% upside, supported by earnings rebound and strategic initiatives. However, risks include fuel cost volatility, competitive pressures, and bearish technical indicators. Investors should weigh solid liquidity and growth initiatives against margin pressures and macroeconomic sensitivities.
SANA Biotechnology trades at $3.775, up 4.57% with strong technical momentum as moving averages signal bullish sentiment. The company shows significant financial challenges with negative ROE (-152.87%) and net income (-$244.17M in 2025), though recent analyst upgrades and clinical developments in cell therapy research provide optimism. Cash flow remains negative but improved from -$55M to -$14M year-over-year, while the stock benefits from 82% buy ratings from analysts.
Investment outlook balances high-risk fundamentals against promising biotechnology breakthroughs. The primary opportunity lies in successful clinical trial outcomes and market adoption of engineered cell therapies, while risks include sustained cash burn, execution challenges, and competitive pressures in the genomics space. Wall Street's $9.50 price target suggests substantial upside potential if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
